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ABSTRACT
This review describes the pathophysiological basis for using procalcitonin to help diagnose infections,
and the strengths and weaknesses of implementing the test rationally in a routine clinical setting. Meta-
analyses of observational studies and intervention studies both suggest that as a surrogate marker,
procalcitonin allows an improved diagnostic assessment of a variety of infections, e.g., respiratory tract
infections, meningitis, acute infectious endocarditis and pancreatitis. Measuring procalcitonin is not a
substitute for careful clinical assessment and obtaining appropriate cultures in all patients. However,
used appropriately, procalcitonin allows an earlier diagnosis of infection and can inform physicians
about the course and prognosis of the disease better than more commonly used clinical and laboratory
markers. With use of a sensitive assay, a procalcitonin-based therapeutic strategy can safely and
markedly reduce antibiotic usage in those respiratory tract infections that are mostly viral, and in viral
meningitis. More sensitive procalcitonin assays, with a functional sensitivity within the normal reference
range of <0.03 lg ⁄L, should be available soon. There is a need for more intervention studies in other
sites of infection to tackle the existing vicious cycle of antibiotic overuse and emerging multiresistance.
Furthermore, as procalcitonin is a hormokine mediator, its immunoneutralisation might open new
treatment options for sepsis.
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INTRODUCTION
Despite important developments in diagnostic
methods and broad-spectrum antibiotics, lower
respiratory tract infections (LRTIs) remain a lead-
ing cause of death in hospitalised patients [1]. At
the same time, both upper and lower respiratory
tract infections remain the most common cause of
unnecessary antibiotic treatments in the commu-
nity [2–4].
The interpretation of clinical response in
patients with bacterial infections, including
LRTIs, lacks standardisation and validation, and
is therefore prone to inter-observer variability. To
improve routine clinical care, an ideal marker for
bacterial infections should allow an early diagno-
sis and provide information about the course and
prognosis of the disease. Traditional clinical signs
of infection (e.g., fever) and routine laboratory
tests (e.g., white blood cell count) can be helpful
in individual cases. However, these tests lack
diagnostic accuracy and are sometimes even
misleading. A positive microbial culture result
has a relatively high speciﬁcity, but even this is
not a reference standard, because it lacks sensi-
tivity and is subject to a delay of 2–3 days.
Although rapid tests exist for some pathogens,
these can lack speciﬁcity in some clinical situa-
tions. For example, the immunochromatographic
urine test for Streptococcus pneumoniae lacks spe-
ciﬁcity in patients with pneumococcal carriage,
such as young children [5] and patients with
chronic obstructive lung disease (COLD). While
clinical risk scores for LRTIs, namely pneumonia,
are available, most do not measure the severity of
the disease but rather the risk of death, which is
greatly inﬂuenced by age and the presence of co-
morbidities [6]. Indeed, LRTI diagnosis and mon-
itoring is complicated in several patient groups,
including infants and elderly patients, immuno-
suppressed patients, and patients with basal
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systemic inﬂammatory response syndrome
(intensive care, post-operative or post-traumatic)
or ventilator-associated pneumonia. Thus, there
remains a need for a reliable marker for use in
assessing the aetiology and severity of LRTIs, and
hence in guiding antibiotic therapy.
The inﬂammatory response to infection is a
dynamic phenomenon involving multiple cellular
activation processes and reﬂecting a highly com-
plex process dependent on a series of interactions
between a pathogen and the host. Factors depend-
ing on themicroorganism include the genus, strain,
virulence factors, immune-evasion mechanisms,
size of the inoculum, andwhether the microorgan-
ism is intracellular or extracellular. Factors
depending on the host include age, immune status,
site and extent of the infection, and previous
antibiotic treatment. Even genetic polymorphisms
in genes coding for proteins involved in the
inﬂammatory response can inﬂuence the amount
and function of protein produced in response to
bacterial pathogens [7]. For example, there exists a
tendency to septic shock and respiratory failure in
patients with community-acquired pneumonia
(CAP) and different tumour necrosis factor
(TNF)-a polymorphism associations [8].
The measurement of most inﬂammatory cyto-
kines is not useful in LRTI assessment, because of
their short plasma half-life and rapid turn-over,
the presence of blocking factors, and their com-
partmentalised production in the lung [9]. Acute-
phase proteins and the so-called ‘hormokines’
[10] appear to be more reliable, because of their
longer plasma half-lives, lesser variation in daily
levels, and stability in vivo and ex vivo. Certain
well-established laboratory tests now have a role
in the follow-up assessment of pneumonia [11].
C-reactive protein (CRP) levels are elevated in
bacterial infections more than in viral infections,
and in systemic more than in localised infections
[12], and have been shown to have value in
establishing the diagnosis of CAP [13]. Neopterin
is a marker of cell-mediated immunity infections
[14]. Nevertheless, both parameters can be ele-
vated during inﬂammation of non-infectious ori-
gin and hence show low speciﬁcity. Another
disadvantage of CRP in routine care is the
protracted increase, with peak levels 2–3 days
after the infectious insult, and its suppression by
steroid therapy, namely in patients with COLD.
In contrast, procalcitonin appears to be a more
speciﬁc marker of systemic bacterial infection.
Levels of procalcitonin increase several-fold
within hours of an infection and continue to
increase until they reach several thousand times
the normal level. This increase, and especially its
time course, correlates with the severity and
prognosis of the infection [15,16]. This review
outlines the pathophysiology of procalcitonin and
reviews its clinical use in the diagnosis and
monitoring of infection, and in guiding antibiotic
therapy.
PROCALCITONIN
PATHOPHYSIOLOGY
Procalcitonin is a precursor peptide of the hormone
calcitonin. It belongs to a family of functionally
related peptides, including calcitonin gene-related
peptides, adrenomedullin and amylin, and their
respective precursor peptides [10]. These peptides
emerged from duplications from a common ances-
tral calcitonin (CALC) gene. In the absence of
infection, the extra-thyroidal transcription of the
CALC-I gene is suppressed and is restricted to
selective expression in neuro-endocrine cells found
mainly in the thyroid, where the mature hormone
is processed and stored in secretory granules [17].
Microbial infections and various forms of
inﬂammation induce a ubiquitous increase in
CALC-I gene expression and constitutive release
of procalcitonin from all parenchymal tissues and
differentiated cell types throughout the body,
including the liver, kidney, adipocytes and mus-
cle [18]. The greater procalcitonin release from
parenchymal cells, in comparison with circulating
blood cells, indicates a tissue-based rather than a
leukocyte-based mechanism of host defence [19].
Thus, CALC gene products represent a prototype
of hormokine mediators and can follow either a
classical hormonal expression pathway in neuro-
endocrine cells or, alternatively, a cytokine-like
ubiquitous expression pathway [18]. The release
of hormokines can be induced either directly via
microbial toxins (e.g., endotoxin) or indirectly via
a humoral or cell-mediated host response (e.g.,
interleukin (IL)-1b, TNF-a and IL-6) [17]. The
induction can be attenuated by cytokines that are
also released during a viral infection (e.g., inter-
feron-c). In sepsis, the predominance of procal-
citonin as opposed to mature calcitonin is
indicative of a constitutive pathway within cells
lacking secretion granules and, hence, a bypas-
sing of much of the enzymatic processing [17].
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Consequently, there is very little intracellular
storage of procalcitonin in sepsis [18].
Procalcitonin is a potentially harmful medi-
ator involved in the infection response. The
administration of procalcitonin to septic ham-
sters with peritonitis doubled their death rate.
Conversely, immunoneutralising elevated pro-
calcitonin levels with a speciﬁc antiserum
greatly increased the survival rate in septic
hamsters [20] and pigs [21], even when the
antiserum was administered after the animals
were moribund [22]. Several characteristics of
procalcitonin favour its use as a therapeutic
target. In contrast to the transiently increased
classical cytokines, for which immunoneutralisa-
tion trials in humans have been disappointing,
the massive increase in circulating procalcitonin
levels persists for several days. Furthermore, the
procalcitonin level is frequently increased in
overt sepsis, the onset of the increase is early
(within 3 h), and the diagnostic accuracy of its
measurement should greatly improve patient
selection for any study of the therapeutic efﬁ-
cacy of procalcitonin immunoneutralisation and
antibiotic therapy in humans.
DIAGNOSTIC STUDIES OF
PROCALCITONIN
As no reference standard for the diagnosis of a
bacterial infection exists, all observational studies
are prone to bias, and premature results and
conclusions can mislead physicians. Importantly,
the diagnostic accuracy of procalcitonin is com-
pletely dependent on the use of a sensitive assay
in a predeﬁned clinical setting (Fig. 1) [23]. Vir-
tually all published diagnostic studies of procal-
citonin have been done using a manual assay with
a functional sensitivity of approximately 0.3–
0.5 lg ⁄L [24], which is more than ten-fold above
the normal reference values for healthy persons
[23]. This sensitivity is not sufﬁcient to detect
moderately elevated procalcitonin levels, and
thus limits the external validity of these studies
to overt sepsis.
Respiratory tract infection
The most frequent source of sepsis is the lung [16].
In this context, LRTIs, including acute bronchitis,
acute exacerbations of COLD and CAP, can be
viewed as ‘sepsis precursors’. Consequently, as
many as 75% of all antibiotic doses are prescribed
for acute respiratory tract infections, in spite of
their predominantly viral aetiology.
The randomised ‘ProRESP’ intervention study
recently assessed the capability of the procalcito-
nin measurement to identify bacterial LRTIs
requiring antimicrobial treatment in the setting
of an emergency department [25]. Procalcitonin
was chosen as the test marker because of its
advantages over CRP and other inﬂammatory
markers, namely an earlier increase upon infec-
tion, a better negative predictive value, and the
unattenuated increase in the presence of immu-
nosuppressive medication (e.g., steroids in
patients with COLD) [26]. Procalcitonin was
measured using a rapid assay with a functional
sensitivity of 0.06 lg ⁄L (Kryptor PCT; Brahms,
Hennigsdorf, Germany). The assay time for pro-
calcitonin measurements was less than 20 min,
and results were routinely available within 1 h
(24 h a day, 7 days per week).
Investigating physicians used an algorithm
developed at the University Hospital, Basel, Swit-
zerland to classify the patients in the procalcitonin
Fig. 1. Rational use of procalcitonin in routine clinical
practice. These cut-off ranges are dependent on the clinical
context and have to be adapted accordingly. For example,
lower cut-off ranges are appropriate in patients with
markedly impaired pulmonary reserve, and higher cut-off
ranges are appropriate in patients with systemic inﬂam-
matory response syndrome on an intensive care unit. The
course of procalcitonin yields important additional infor-
mation, and follow-up measurements can be helpful to
improve diagnostic accuracy and to support treatment
decisions. The use of rapid and sensitive assays is needed
for antibiotic stewardship. (Adapted and updated from
Christ-Crain M, Mu¨ller B. Procalcitonin in bacterial
infections – hype, hope, more or less? SwissMedWkly
2005; 135: 451–60.) COLD, chronic obstructive lung disease;
ICU, intensive care unit; PCT, procalcitonin; RTI, respirat-
ory tract infection.
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group into four subgroups according to the prob-
ability of bacterial infection (Fig. 2). The following
procalcitonin cut-off ranges were derived by
calculating multilevel likelihood ratios:
• A procalcitonin level of <0.1 lg ⁄L suggested
the absence of bacterial infection, and the
initiation or continuation of antibiotics was
strongly discouraged. Antibiotic therapy could
be considered in critically ill patients (Fig. 2). If
antibiotics were given, an early discontinu-
ation of antibiotic therapy after 1–3 days was
endorsed if procalcitonin levels, checked daily,
remained at <0.1 lg ⁄L.
• A procalcitonin level between 0.1 and 0.25 lg ⁄L
indicated that bacterial infection was unlikely,
and the initiation or continuation of antibiotics
was discouraged. Antibiotic therapy can be
considered in high-risk patients. Again, if anti-
biotics were given, early termination was
endorsed if procalcitonin levelsdid not increase.
• A procalcitonin level between 0.25 and 0.5 lg ⁄L
indicated a possible bacterial infection, and the
initiation or continuation of antibiotic therapy
was encouraged.
• A procalcitonin level of >0.5 lg ⁄L strongly
suggested the presence of bacterial infection,
and antibiotic treatment and continuation was
strongly encouraged [25].
The same cut-offs were used regardless of
whether patients had been pretreated with anti-
biotics prior to admission to the emergency
department.
Re-evaluation of the clinical status and meas-
urement of serum procalcitonin levels was recom-
mended after 6–24 h in all persistently sick and
hospitalised patients in whom antibiotics were
withheld. The procalcitonin algorithm could be
overruled in patients with immediately life-threat-
ening disease (e.g., patients with the most severe
co-morbidities, patients with emerging need for
intensive care unit admission during the initial
follow-up, patients with haemodynamic or respir-
atory instability, and very ill patients with a
positive antigen test result for legionellosis).
Physicians were advised that persistently ele-
vated procalcitonin levels may indicate a compli-
cated course (e.g., antibiotic resistance or abscess),
while procalcitonin levels may remain relatively
low in localised infections. Procalcitonin levels
were reassessed on days 4, 6 and 8 in hospitalised
patients receiving ongoing antibiotic therapy, and
in patients showing a worsening or delayed
recovery of signs and symptoms, and antibiotic
was discontinued according to the procalcitonin
cut-offs deﬁned above. In patients with very
high procalcitonin values upon admission (e.g.,
>10 lg ⁄L), discontinuation of antibiotic therapy
was encouraged if levels decreased to below 80–
90% of the initial value. In patients with an initial
procalcitonin level >10 lg ⁄L and smaller reduc-
tions during follow-up, continuation of antibiotic
treatment was encouraged.
In the procalcitonin groupof theProRESP-study,
the percentage of patients with LRTI who received
antibiotic therapy was reduced by almost 50%, as
compared with the standard group [25]. The
clinical and laboratory outcomes were similar in
both groups. Reduced antibiotic use was most
striking in cases of acute bronchitis and acute
exacerbations of COLD. COLD exacerbations pre-
sent a particular challenge in terms of diagnosing
an infectious cause. Themajority of COLD patients
have positive sputum culture results, although
these do not necessarily imply an active infection.
In the procalcitonin group, positive culture rates
were similar in patients in whom antibiotics were
given or withheld, as were outcomes, underlining
the limited diagnostic usefulness of sputum cul-
tures in COLD patients. Since patients with COLD
have an impaired pulmonary reserve and the
Fig. 2. Protocol for the classiﬁcation, management and
monitoring of patients according to the procalcitonin level
and the associated probability of bacterial infection, as
used in the ‘ProRESP’ and the ‘ProCAP’ study [25]. CAP,
community-acquired pneumonia; COLD, chronic obstruct-
ive lung disease; CURB, confusion, urea nitrogen, respir-
atory rate, blood pressure; GOLD, Global Initiative for
Chronic Obstructive Lung Disease; ICU, intensive care
unit; PCT, procalcitonin; PSI, Pneumonia Severity Index;
SaO2, arterial blood oxygen saturation. *Involving Staphy-
lococcus aureus, Klebsiella pneumoniae, anaerobic organisms,
empyema or abscesses.
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infectionmight be locally restricted, aprocalcitonin
cut-off level for withholding antibiotics of
<0.1 lg ⁄L is advisable in patients with severe
disease. This was validated in the ProCOLD study
(ISRCTN77261143), which included more than 200
patients [27].
In the clinical context of CAP, the primary
value of procalcitonin on admission lies not in the
reduction of antibiotic prescriptions, but in faci-
litating and expediting the differential diagnosis
of new or progressing inﬁltrates. Accordingly,
procalcitonin guidance could markedly lower the
number of antibiotic courses in patients with
inﬁltrates on chest X-ray unrelated to pneumonia.
Recently, the ProCAP study (ISRCTN04176397),
involving over 300 patients with CAP requiring
hospitalization, showed that procalcitonin guid-
ance allowed a marked reduction in the duration
of antibiotic treatment from a median of 12 days
to 5 days [28].
Procalcitonin may also be useful as a prognostic
parameter in patients with ventilator-associated
pneumonia [29,30]. Whether procalcitonin guid-
ance can reduce the high levels of unnecessary
antibiotic use in upper and lower respiratory
infections in community practice is also being
investigated (PARTI ⁄ProDOC-study, ISRCTN7
3182671) [31].
Several studies have demonstrated the comple-
mentary utility of procalcitonin and other mark-
ers in LRTIs. In children, CRP and procalcitonin
showed a signiﬁcant association with the bacterial
aetiology of LRTIs [32]. In the differentiation of
pneumococcal and atypical infections (i.e., Myco-
plasma and Chlamydia spp.) from viral infections,
CRP yielded better sensitivity, but procalcitonin
was more speciﬁc. Procalcitonin was also more
speciﬁc in differentiating pneumococcal infec-
tions from all other aetiologies combined, while
the two tests showed similar sensitivity in this
regard. Thus, procalcitonin and CRP measure-
ment may have an additive value in rationalising
antibiotic therapy before microbiological results
are obtained.
Another study examined the usefulness of
procalcitonin and neopterin in distinguishing
different aetiologies, and assessing infection
severity, in adults with CAP [33]. Pneumococcal
pneumonia was the only aetiology that presented
with elevated levels of both procalcitonin and
neopterin, which were especially high in bacter-
aemic pneumonia. In the case of Legionella pneu-
monia, neopterin levels were greatly increased
while procalcitonin levels were only moderately
elevated. Finally, infections with Mycobacterium
tuberculosis and with Pneumocystis jiroveci were
associated with elevated neopterin levels and low
or undetectable procalcitonin levels. Thus, neop-
terin was more elevated in infections with cell-
mediated immunity. Patients with both pneumo-
coccal and Legionella pneumonia were stratiﬁed
using the Pneumonia Severity Index, and patients
in high-risk classes (IV and V) had signiﬁcantly
more elevated procalcitonin levels. Both procalc-
itonin and neopterin levels were signiﬁcantly
more elevated when patients presented with
multilobar radiographic inﬁltrates.
Other infections
Procalcitonin can also be helpful in the diagnosis of
bacterial infections at extra-pulmonary sites [34]. A
recentmeta-analysis showed that procalcitonin is a
more accurate marker for systemic bacterial infec-
tions than is CRP, independent of the infection
source. The superiority of procalcitoninwas appar-
ent both when differentiating bacterial infections
from non-infective causes of inﬂammation and
when differentiating bacterial infections from viral
infections [24]. On pooled analysis, procalcitonin
showed a sensitivity of 88% (95% CI 80–93) and a
speciﬁcity of 81% (95% CI 67–90). Procalcitonin
was the only independent predictor of acute
infectious endocarditis upon admission in a mul-
tivariate analysis. Its diagnostic accuracy was
comparable to that of B-type natriuretic peptide
for the emergency diagnosis of heart failure [35].
However, procalcitonin levels may remain very
low in some patients with sub-acute endocarditis.
Patients with oedematous or toxic pancreatitis
have low concentrations of procalcitonin, whereas
patients with infectious pancreatitis have very
high procalcitonin concentrations. Increased pro-
calcitonin levels may reﬂect the derangement in
gut barrier function and may hence predict those
patients in whom the translocation of bacteria into
dead pancreas, with consequent infected necrosis,
is more likely. Data on the clinical use of procal-
citonin in diverticulitis or other gastrointestinal
infections are lacking [34].
Procalcitonin may be useful in the diagnosis of
urinary tract infections, for which there are no
well-identiﬁed severity markers. In children, pro-
calcitonin was correlated with the severity of
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renal scars caused by urinary infection (as
assessed by scintigraphy), while TNF-a, IL-6,
IL-8 and CRP showed no such correlation
[36,37]. Procalcitonin is also helpful in differenti-
ating between viral and bacterial meningitis [15]
and can facilitate antibiotic stewardship during
an epidemic of viral meningitis [38]. As expected,
localised infections yield lower procalcitonin lev-
els than generalised infections, and positive blood
cultures. In a closed focus of infection, procalci-
tonin concentrations are only moderately high, as
in some cases of infectious arthritis in adults.
Other than bacterial infections, malaria is the
main condition in which procalcitonin concentra-
tions are high. These elevated procalcitonin levels
are probably due to elevated TNF-a levels, as
large quantities of procalcitonin are produced
after perfusion of TNF-a in humans.
LIMITATIONS OF PROCALCITONIN
AS A MARKER
The potential limitations and weaknesses of pro-
calcitonin as a marker are listed in Table 1 [34]. In
cases of ‘falsely’ high procalcitonin levels in the
absence of an infection, typically seen after severe
trauma or surgery, procalcitonin levels are usually
moderately elevated, between 1 and 10 lg ⁄L, but
decline rapidly to values below1 lg ⁄Lwithin 48 h.
Persistently high procalcitonin levels in these
patients indicate that a complicating bacterial
infection is likely to be present. Conversely, ini-
tially falsely lowprocalcitonin levels, typically seen
during the early course or localised state of an
infection, often show a gradual increase during
follow-up measurements after 6–24 h and thereby
point to an underlying bacterial disease. This
further underlines the importance of follow-up
measurements. Procalcitonin had no clear useful-
ness in the diagnosis of fungal infections, even
when severe (e.g., invasive aspergillosis) [39,40].
Also, the severity of some viral infections (e.g.,
cytomegalovirus) cannot be assessed using pro-
calcitonin.
To establish the promising ﬁndings from the
ProRESP, ProCAP, ProCOLDandProDOC ⁄PARTI
studies as an international standard of care, resid-
ual limitations have to be resolved. Three of the
four studies were performed at a single university
hospital, which raises questions concerning their
external validity. Standard care was used in the
control group, and theuse of very recent guidelines
was not strictly enforced. Only the Pro-
DOC ⁄PARTI study, a non-inferiority study enrol-
ling 50 family physicians, had adequate power to
assess clinical outcome. However, the low rate of
adverse events in the outpatient setting of primary
care is arguably not representative for hospitalised
patients and their higher complication rates.
Finally, despite a marked reduction in duration of
antibiotic therapy in the procalcitonin group with-
in the ProCAP study, the overall length of hospital
stay was not the target of intervention and was
therefore similar between the treatment groups.
Some experts argue that once a patient is clinically
stable and intravenous antibiotics are discontin-
ued, then discharge from the hospital should be
safe unless there are extenuating circumstances.
Cost-effectiveness is relevant in a public health
perspective.
Further research is also required to elucidate
the role of biomarkers during infection in order to
assess immunomodulating therapies. Procalcito-
nin has a role in several steps of the inﬂammatory
response, such as calcium homeostasis [41], nitric
oxide synthesis [42] and chemotaxis [43,44], and
immunoneutralisation of procalcitonin has been
shown to be useful as a therapy for sepsis in
animal models [22].
CONCLUSION
As is the case for all diagnostic tests, serum
procalcitonin levels must always be evaluated
and re-evaluated during follow-up, and inter-
preted with regard to a careful clinical and micro-
biological assessment. The diagnosis of all serious
infections will continue to require a high level of
suspicion, a careful history and a thorough phys-
ical examination and blood cultures in all patients.
Clinicians should withstand the temptation to rely
solely on the result of laboratory tests rather than a
demanding clinical assessment. Moreover, clini-
cians must bear in mind the limitations of every
biomarker, the causes of false-positive and false-
negative results, and the time kinetics of the test.
Also, one must consider the diagnostic accuracy of
the test in each group of patients, and in every
infection aetiology. Clinically apparent infections
are a sequel of variable interactions between host
immune response, microbes and their toxins, and
are far too complex to be reduced to a single cut-off
value of any speciﬁc surrogate marker. Optimal
test cut-offs also depend on the clinical setting, the
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age of the patient, the extent of the infection, and
the presence of co-morbidities.
Despite these caveats, the likelihood and prog-
nosis of bacterial infection strongly correlate with
procalcitonin levels. Cut-off ranges for the diag-
nosis of bacterial infections and for antibiotic
stewardship have been developed and validated
in several intervention trials in respiratory tract
infections (ProRESP, ProCAP, ProCOLD, Pro-
DOC ⁄PARTI), which enrolled over 1000 patients.
In addition, a French study was successful in
safely controlling antibiotic use during a menin-
gitis outbreak in children. Thus, procalcitonin
assays might expedite the diagnostic assessment
of infections and the installation of adequate
therapeutic measures, and help to improve
resource utilisation, e.g., of diagnostic imaging.
In the future, additional emerging biomarkers are
likely to complement the diagnostic and prognos-
tic power of procalcitonin. Thus, the optimal use
of such tests may involve serial measurement, in
carefully selected patients, of a combination of
biomarkers.
There is a need for more intervention studies of
procalcitonin in other sites of infection to tackle
the existing vicious cycle of antibiotic overuse and
emerging multiresistance. Furthermore, as pro-
calcitonin is a hormokine mediator, its immuno-
neutralisation might provide new treatment
options for sepsis.
Table 1. Potential limitations of procalcitonin as a marker (adapted and updated from Christ-Crain M, Mu¨ller B.
Procalcitonin in bacterial infections – hype, hope, more or less? SwissMedWkly 2005; 135: 451–60.)
The optimal cut-off ranges of procalcitonin are variable and dependent on:
the clinical setting (e.g., primary care, emergency room, intensive care unit, post-operative or trauma care units)
the site and extent of the infection (e.g., RTI, endocarditis, meningitis)
co-morbidities (e.g., impaired pulmonary reserve, immunosuppression)
the clinical implications (e.g., diagnosis, prognosis, antibiotic stewardship)
For many infections, the optimal cut-off ranges remain to be determined in observational studies
using sensitive assays and validated in intervention studies
Common causes of false-negative and false-positive results:
False-positive (i.e. falsely high levels in the absence of a bacterial infection):
physiological status of newborns (ﬁrst days of life)
acute respiratory distress syndrome
acute attacks of Plasmodium falciparum malaria
systemic fungal infections (e.g., candidiasis, aspergillosis)
severe mechanical trauma
post surgical trauma
administration of monoclonal or polyclonal anti-thymocyte globulin in the
treatment of acute rejection after transplantation
chemical pneumonitis
severe burns and heat strokes
medullary thyroid cancer, small cell cancer of the lung, some carcinoid tumours,
tumours with paraneoplastic hormone production
inﬂammation associated with ‘cytokine storms’, e.g., IL-1b in familial Mediterranean fever,
therapeutic infusions of TNF-a (e.g., for melanoma)
False-negative (i.e., falsely low levels in the presence of a bacterial infection):
very early course of infections
localised and sub-acute infections (e.g., endocarditis)
Procalcitonin is not an immediate marker of infection. Follow-up and re-evaluation of
procalcitonin upon clinical suspicion of infection and during the course of the disease is pivotal
A single procalcitonin value upon admission is not a very good prognostic marker
Although it is higher in patients who survive than in non-survivors, procalcitonin is a diagnostic
rather than a prognostic marker. In contrast, the course of procalcitonin has strong prognostic implications
Costs
Procalcitonin is more expensive than other, less reliable, biomarkers (e.g. CRP),
for which, however, no intervention studies exist
Different assays available with very different test performances
The diagnostic accuracy of procalcitonin is completely dependent on the use of a sensitive assay in an
appropriate, deﬁned clinical setting
Ultrasensitive assays to determine subtle elevations of procalcitonin are not yet widely available
CRP, C-reactive protein; IL, interleukin; RTI, respiratory tract infection; TNF-a, tumour necrosis factor a.
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